The approval comes on the back of the SOUL Phase 3b trial, which evaluated the effects of the 14-mg dose in reducing the risk of MACE in high-risk diabetic adults. Ultimately, the 14-mg oral ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In the SOUL trial, Rybelsus reduced risk for heart ...
On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect ...
The US Food and Drug Administration (FDA) has approved the first oral GLP-1 receptor agonist, Rybelsus (semaglutide), to help prevent heart attack and stroke in adults with type 2 diabetes and high ...
Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...
Oral semaglutide (Rybelsus) can now be used to reduce major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk, following the US Food and Drug Administration’s ...
Oral semaglutide is now approved to reduce cardiovascular risk in high-risk type 2 diabetes patients, marking a first for oral GLP-1 receptor agonists. The SOUL trial showed a 14% relative risk ...
VIENNA — Oral semaglutide showed similar reductions in cardiovascular events in patients with type 2 diabetes (T2D) and cardiovascular or chronic kidney disease with and without peripheral artery ...
The ZENITH trial demonstrated sotatercept's efficacy in reducing severe outcomes in high-risk PAH, leading to early trial termination for efficacy. Oral semaglutide in the SOUL trial reduced major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results